R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II trial to study the effectiveness of R115777 in treating patients who have metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Tipifarnib

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the pancreas

• Measurable metastatic disease No prior treatment for metastatic disease except immunotherapy (e.g., antibodies, vaccines, cytokines)

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Performance status: ECOG 0-2

• WBC at least 4,000/mm3 OR granulocyte count at least 1,500/mm3

• Platelet count at least 100,000/mm3

• Bilirubin no greater than 2.0 mg/dL

• SGOT/SGPT no greater than 2 times normal

• Creatinine no greater than 2.0 mg/dL OR creatinine clearance at least 50 mL/min

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for 3 months after the study

• No concurrent illness or active infection which would preclude study

• No prior malignancy allowed unless disease free for the time period considered appropriate for cure of the specific cancer

• No history of allergies to imidazole compounds (e.g., fluconazole, ketoconazole, miconazole, itraconazole, clotrimazole)

PRIOR CONCURRENT THERAPY:

• No prophylactic filgrastim (G-CSF), sargramostim (GM-CSF), or thrombopoietin

• Primary neoadjuvant or adjuvant chemotherapy allowed at least 6 months prior to detection of metastatic disease

• Primary radiotherapy allowed at least 6 months prior to detection of metastatic disease

• No concurrent use of proton pump inhibitors (e.g., omeprazole)